Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …

Diabetes mellitus is one of the major risk factors for cognitive dysfunction. The pathogenesis
of brain impairment caused by chronic hyperglycemia is complex and includes …

Dementia is a permanent illness characterized by mental instability, memory loss, and
cognitive decline. Many studies have demonstrated an association between diabetes and …

In the last decade, attention has become greater to the relationship between
neurodegeneration and abnormal insulin signaling in the central nervous system, as insulin …

Background We investigated the effects of liraglutide, a glucagon-like peptide-1 (GLP-1)
agonist, on a depression-like phenotype in mice exposed to chronic unpredictable stress …

Insulin resistance (IR) is a metabolic state preceding development of type 2 diabetes (DM2),
cardiovascular disease, and neurodegenerative disorders, including Alzheimer's Disease …

Diabetes is a complex disease characterized by hyperglycemia, together with polyuria,
polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic …

Type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) commonly co‐occur. T2DM
increases the risk for AD by approximately twofold. Animal models provide one means of …

ABSTRACT Glucagon-like peptide 1 (GLP-1) is a target for treatment of diabetes; however,
its function in the brain is not well studied. In this systematic review, we aimed to analyze the …

Parkinson's disease (PD) is the most common neurodegenerative disorder with motor
symptoms. The neuropathological alterations characterizing the brain of patients with PD …